Christopher Hourigan

Last updated
Christopher Hourigan
Alma mater Oxford University
Known for Acute Myeloid Leukemia and Measurable Residual Disease
Awards Alpha Omega Alpha, Johns Hopkins Chapter
Honorary Fellow, Royal College of Physicians,
NHLBI Directors Award
NHLBI Orloff Award
NIH Bench to Bedside Award
NIH Directors Challenge Innovation Award
American College of Physicians Early Career Physician Award
American Society for Clinical Investigation Young Physician-Scientist Award
Presidential Early Career Award for Scientists and Engineers (2019)
Scientific career
Institutions National Institutes of Health
Website https://www.nhlbi.nih.gov/science/myeloid-malignancies

Christopher Hourigan is a physician-scientist known for work on measurable residual disease (MRD; previously termed minimal residual disease) in acute myeloid leukemia. [1] [2] [3] [4] [5] [6] [7]

Contents

He was previously Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute and founding co-director of the Myeloid Malignancies Program at the National Institutes of Health in Bethesda, Maryland. [8]

Education

Hourigan graduated from Oxford University Medical School and received his DPhil for work with Sir John Bell (physician) at the Weatherall Institute of Molecular Medicine at Oxford University. He completed postdoctoral clinical training at Guy's and St Thomas' Hospital in London, Johns Hopkins Bayview Medical Center, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore. [8] He is board certified in Internal Medicine, Hematology, and Medical Oncology.

Research

Hourigan is best known for work on Measurable Residual Disease (MRD) and precision medicine in Acute Myeloid Leukemia (AML). This included the demonstration that intervention in patients with AML MRD may improve survival, [9] [10] [11] [12] [13] [14] [15] [16] [17] that low-level TP53 mutations are detectable pre-transplantation in patients with sickle cell disease who develop myeloid malignancy after hematopoietic stem cell transplantation, and that patient-personalized single cell sequencing can distinguish mutations associated with non-malignant cells rather than residual AML. [18] He has held senior leadership positions in the European Leukemia Network (ELN) guidelines committee for AML MRD, the Foundation for the National Institutes of Health (FNIH) biomarkers consortium for AML MRD, the National Cancer Institute (NCI) MyeloMATCH precision medicine initiative, the Center for International Blood and Marrow Transplant Research (CIBMTR), and on the American Society of Hematology (ASH) guidelines committee for AML in older adults.

Honors and awards

In 2019, Hourigan received a Presidential Early Career Award for Scientists and Engineers for his research on Measurable Residual Disease in Acute Myeloid Leukemia. [19]

In 2020, Hourigan was awarded the National Heart, Lung, and Blood Institute Orloff Award [20] and honored for one of the top NIH accomplishments of 2020. [21]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Leukemia</span> Blood cancers forming in the bone marrow

Leukemia is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

<span class="mw-page-title-main">Chronic lymphocytic leukemia</span> Bone marrow cancer in which lymphocytes are overproduced

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. In patients with CLL, B cell lymphocytes can begin to collect in their blood, spleen, lymph nodes, and bone marrow. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types:

  1. Slow-growing CLL
  2. Fast-growing CLL
<span class="mw-page-title-main">Hematopoietic stem cell transplantation</span> Medical procedure to replace blood or immune stem cells

Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood, in order to replicate inside a patient and produce additional normal blood cells. HSCT may be autologous, syngeneic, or allogeneic.

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Tumors that affect the blood, bone marrow, lymph, and lymphatic system

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Myeloid sarcoma</span> Medical condition

A myeloid sarcoma is a solid tumor composed of immature white blood cells called myeloblasts. A chloroma is an extramedullary manifestation of acute myeloid leukemia; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow.

<span class="mw-page-title-main">Acute myeloid leukemia</span> Cancer of the myeloid line of blood cells

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly, and is typically fatal within weeks or months if left untreated.

<span class="mw-page-title-main">Acute myeloblastic leukemia with maturation</span> Medical condition

Acute myeloblastic leukemia with maturation (M2) is a subtype of acute myeloid leukemia (AML).

<span class="mw-page-title-main">CD135</span> Protein found in humans

Cluster of differentiation antigen 135 (CD135) also known as fms like tyrosine kinase 3, receptor-type tyrosine-protein kinase FLT3, or fetal liver kinase-2 (Flk2) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. CD135 is the receptor for the cytokine Flt3 ligand (FLT3L).

Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission. Sensitive molecular tests are either in development or available to test for MRD. These can measure minute levels of cancer cells in tissue samples, sometimes as low as one cancer cell in a million normal cells, either using DNA, RNA or proteins.

<span class="mw-page-title-main">Childhood leukemia</span> Medical condition

Childhood leukemia is leukemia that occurs in a child and is a type of childhood cancer. Childhood leukemia is the most common childhood cancer, accounting for 29% of cancers in children aged 0–14 in 2018. There are multiple forms of leukemia that occur in children, the most common being acute lymphoblastic leukemia (ALL) followed by acute myeloid leukemia (AML). Survival rates vary depending on the type of leukemia, but may be as high as 90% in ALL.

Timothy J. Ley

Timothy J. Ley is an American hematologist and cancer biologist. He is the Lewis T. and Rosalind B. Apple Professor of Oncology in the department of medicine, and is chief of the section of stem cell biology in the division of oncology at Washington University in St. Louis. He is a member of the Alvin J. Siteman Cancer Center.

Graft-versus-tumor effect (GvT) appears after allogeneic hematopoietic stem cell transplantation (HSCT). The graft contains donor T cells that can be beneficial for the recipient by eliminating residual malignant cells. GvT might develop after recognizing tumor-specific or recipient-specific alloantigens. It could lead to remission or immune control of hematologic malignancies. This effect applies in myeloma and lymphoid leukemias, lymphoma, multiple myeloma and possibly breast cancer. It is closely linked with graft-versus-host disease (GvHD), as the underlying principle of alloimmunity is the same. CD4+CD25+ regulatory T cells (Treg) can be used to suppress GvHD without loss of beneficial GvT effect. The biology of GvT response is still not fully understood but it is probable that the reaction with polymorphic minor histocompatibility antigens expressed either specifically on hematopoietic cells or more widely on a number of tissue cells or tumor-associated antigens is involved. This response is mediated largely by cytotoxic T lymphocytes (CTL) but it can be employed by natural killers as separate effectors, particularly in T-cell-depleted HLA-haploidentical HSCT.

FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). The acronym incorporates the three primary ingredients of the regimen:

  1. Fludarabine: an antimetabolite that, while not active toward AML, increases formation of an active cytarabine metabolite, ara-CTP, in AML cells;
  2. Arabinofuranosyl cytidine : an antimetabolite that has been proven to be the most active toward AML among various cytotoxic drugs in single-drug trials; and
  3. Granulocyte colony-stimulating factor (G-CSF): a glycoprotein that shortens the duration and severity of neutropenia.

Microtransplantation (MST) is an advanced technology to treat malignant hematological diseases and tumors by infusing patients with granulocyte colony-stimulating factor (G-CSF) mobilized human leukocyte antigen (HLA)-mismatched allogeneic peripheral blood stem cells following a reduced-intensity chemotherapy or targeted therapy. The term "microtransplantation" comes from its mechanism of reaching donor cell microchimerism.

Guo Mei is a hematologist and associate director of 307th Hospital of Chinese People’s Liberation Army and deputy director of Radiation Research Institute.

<span class="mw-page-title-main">Shimon Slavin</span> Israeli professor of medicine

Shimon Slavin is an Israeli professor of medicine. He pioneered immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation to cure hematological malignancies and solid tumors. He also used hematopoietic stem cells to induce transplantation tolerance to bone marrow and organ allografts.

Christine Joyce Britch is a Professor of Childhood Cancer Cytogenetics at Newcastle University. She works on acute leukemia and used cytogenetics to optimise treatment protocols.

<span class="mw-page-title-main">Bisantrene</span> Chemical compound

Bisantrene is an anthracenyl bishydrazone with anthracycline-like antineoplastic activity and an antimetabolite. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in chemotherapeutic activity, but unlike anthracyclines like doxorubicin, it exhibits little cardiotoxicity.

<span class="mw-page-title-main">Brunangelo Falini</span> Italian hematologist, academic and researcher

Brunangelo Falini is an Italian hematologist, academic and researcher. He is a Full Professor of Hematology, and Head of the Institute of Hematology and Bone Marrow Transplantation at University of Perugia.

<span class="mw-page-title-main">Bob Löwenberg</span>

Bob Löwenberg is a clinical hematologist/investigator. He is a professor of hematology at Erasmus University Rotterdam.

References

  1. ↑ Search Results for author Hourigan CS on PubMed .
  2. ↑ Google Scholar Author page, Accessed Dec. 25, 2021
  3. ↑ Schuurhuis, Gerrit J.; Heuser, Michael; Freeman, Sylvie; Béné, Marie-Christine; Buccisano, Francesco; Cloos, Jacqueline; Grimwade, David; Haferlach, Torsten; Hills, Robert K.; Hourigan, Christopher S.; Jorgensen, Jeffrey L. (2018-03-22). "Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party". Blood. 131 (12): 1275–1291. doi:10.1182/blood-2017-09-801498. ISSN   0006-4971. PMC   5865231 . PMID   29330221.
  4. ↑ Tyner, Jeffrey W.; Tognon, Cristina E.; Bottomly, Daniel; Wilmot, Beth; Kurtz, Stephen E.; Savage, Samantha L.; Long, Nicola; Schultz, Anna Reister; Traer, Elie; Abel, Melissa; Agarwal, Anupriya (17 October 2018). "Functional genomic landscape of acute myeloid leukaemia". Nature. 562 (7728): 526–531. Bibcode:2018Natur.562..526T. doi:10.1038/s41586-018-0623-z. ISSN   1476-4687. PMC   6280667 . PMID   30333627.
  5. 1 2 Hourigan, Christopher S.; Karp, Judith E. (2013). "Minimal residual disease in acute myeloid leukaemia". Nature Reviews Clinical Oncology. 10 (8): 460–471. doi:10.1038/nrclinonc.2013.100. ISSN   1759-4782. PMC   4163748 . PMID   23799371.
  6. 1 2 Hourigan, C. S.; Gale, R. P.; Gormley, N. J.; Ossenkoppele, G. J.; Walter, R. B. (2017). "Measurable residual disease testing in acute myeloid leukaemia". Leukemia. 31 (7): 1482–1490. doi:10.1038/leu.2017.113. ISSN   1476-5551. PMID   28386105. S2CID   1297753.
  7. ↑ "Christopher S. Hourigan". scholar.google.com. Retrieved 2021-11-23.
  8. 1 2 "Principal Investigators". NIH Intramural Research Program. Retrieved 2021-11-03.
  9. ↑ Hourigan, C (2020). "Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia with Genomic Evidence of Residual Disease". Journal of Clinical Oncology. 38 (12). European Hematology Association: 1273–1283. doi:10.1200/JCO.19.03011. PMC   7164487 . PMID   31860405 . Retrieved 26 November 2021.
  10. ↑ Osterweil, Neil (2019-06-25). "MDedge Hematology News". AML variants before transplant signal need for aggressive therapy.
  11. ↑ Lovely, Brittany (2019-08-15). "OncLive". AML Findings Suggest a Broader Role for Genomic Testing. Vol. 20, no. 16.
  12. ↑ Melville, Nancy (2019-06-25). "Medscape". Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk.
  13. ↑ "ecancer". EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?. 2019-06-14.
  14. ↑ Hourigan, Christopher S.; Dillon, Laura W.; Gui, Gege; Logan, Brent R.; Fei, Mingwei; Ghannam, Jack; Li, Yuesheng; Licon, Abel; Alyea, Edwin P.; Bashey, Asad; Deeg, H. Joachim (2020-04-20). "Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease". Journal of Clinical Oncology. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. ISSN   0732-183X. PMC   7164487 . PMID   31860405.
  15. ↑ Stenger, Matthew (2020-01-17). "The ASCO Post". Conditioning Intensity for Allogeneic Transplantation in Patients With AML. Retrieved 27 November 2021.
  16. ↑ Kuznar, Wayne (2020-02-26). "MEDPAGE TODAY". Christopher Hourigan, DM, DPhil, on Mutation-based MRD and Conditioning for AML.
  17. ↑ Llobet-Canela, Marta (2020-08-26). "AML Hub". Patients with pretransplant MRD may benefit from conditioning intensification.
  18. ↑ "Mission Bio's Tapestri Platform Used to Distinguish Acute Myeloid Leukemia Clones from CHIP Clones". CISION PR Newswire.
  19. ↑ "President Donald J. Trump Announces Recipients of the Presidential Early Career Award for Scientists and Engineers – The White House". trumpwhitehouse.archives.gov. Retrieved 2021-11-03.
  20. ↑ "NHLBI Orloff Award 2020: Chris Hourigan". YouTube .
  21. ↑ "Changing fate by personalizing treatment for a high-risk blood cancer". 30 December 2020.
  22. ↑ Hourigan, Christopher S.; Dillon, Laura W.; Gui, Gege; Logan, Brent R.; Fei, Mingwei; Ghannam, Jack; Li, Yuesheng; Licon, Abel; Alyea, Edwin P.; Bashey, Asad; Deeg, H. Joachim (2020-04-20). "Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease". Journal of Clinical Oncology. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. ISSN   0732-183X. PMC   7164487 . PMID   31860405.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.